Abstract
The renin-angiotensin system plays a pivotal role in the pathophysiology of heart failure. ACE inhibitors block the production of angiotensin II and are efficacious in the therapy of patients with heart failure, ACE inhibitors have combined preload and afterload reducing effects. Cardiac index is augmented, cardiac filling pressures are reduced and renal function may improve with ACE Inhibition. Long-term subjective and objective improvements have been reported. Preliminary data suggest that this class of vasodilators may favorably influence the prognosis of advanced heart failure.